Patrys Limited (ASX:PAB)

Market Cap	11.24M
Revenue (ttm)	828.54K -40.6%
Net Income	-3.01M
EPS	-0.02
Shares Out	340.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	484,091
Average Volume	322,304
Open	0.0330
Previous Close	0.0330
Day's Range	0.0320 - 0.0340
52-Week Range	0.0120 - 0.0490
Beta	0.61
RSI	59.12
Earnings Date	Feb 23, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is base...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PAB

Financial Performance

In 2025, Patrys's revenue was 828,540, a decrease of -40.57% compared to the previous year's 1.39 million. Losses were -3.01 million, -14.86% less than in 2024.